Юцковская Я.А., Маркелова Е.В., Юцковский А.Д.

57
.
(80
80
57
60
'
'
'
),
,
,
β
N. gonorrhoeae
.
'
.
10
.
–
6.
'
.–
1999. – . 67q68.
7.
.
,
,
.
...
'
'
2%'
9.
'
.
,
11%
'
–
9%
96%
.
'
'
.
,
,
'
'
'
,
'
.
1.
.
:
q
.–
.
.//
q
»,
...
.
.
«
q
:
.
.–
.–
q
, 1986.
.,
q
».
.,
.//
. – 2001. –
.
1
:
«
'
,
.
.,
8.
.
10
.//
'
,
:
.,
6. – . 51q53.
.,
.//
. – 1999. –
3. – . 123q127.
.,
.,
5.
'
,
2. – . 51q53.
.,
,
2. – . 36q38.
.,
.
.//
. – 2000. –
1998. –
,
– 10
.//
. – 2000. –
.,
4.
.
,
.,
3.
'
'
'
'
.
,
2.
.,
,
2. – . 20q25.
.,
q
q
01.10.02.
TOPICAL ADMINISTRATION OF TINROSTIM UNDER
CHRONIC GONORRHEA
O.A. Singur, G.I. Turkutyukova
Vladivostok State Medical University, FGU CG SEN at water and
air transport in the FarqEastern Region (Vladivostok)
Summary – This article describes the present'day situation when
against the background of ubiquitous upsurge in the gonorrhea
sickness rate there are both progressive upgrowth of gonococcus
strains, which generate beta'lactamase, and decrease in antibi'
otic susceptibility of microorganisms. On carrying out the anal'
ysis of the gonorrhea sickness rate among Vladivostok residents
during long'term observations (1991'2001), the authors have
studied the prevalence of N. gonorrhoeae strains generating beta'
lactamase and their antibiotic susceptibility. So as to enhance
the efficiency of etiotropic therapy applied to the patients suf'
fering from chronic gonorrhea the physicians have locally used
Tinrostim, the medication developed in TINRO'Center, which
stimulates phagocytosis.
, 1994.
Pacific Medical Journal, 2003, No. 4, p. 55q57.
616.8'053.31:616.972:618.3](571.63)
.
,
.
,
[2,
.
4, 7, 15].
'
'
,
[3, 9, 10].
.
'
'
,
,
[4,
5].
:
,
,
[1].
.
'
'
.
'
58
'
275 (CD22)
.
.
1,5
,
'
'
(24,18±1,77
'
: 0,59±0,07
'
.
(130
145
(1'
).
, 89
(2'
.),
, 94
.)
'
(3'
92
.).
.
50
0,57±0,08
,
.
(CD3),
(CD16), K'
(CD56).
(
,
. 1).
,
.
(CD25, HLA'DR, CD38,
'
'
Statistica 5.
'
'
'
.
'
'
(CD4)
(CD8).
'
(CD4/CD8)
'
CD95) [6].
.
'
'
'
(CD4,
'
,
CD8), N
21,63±1,05%),
,
CD38'
.
[6, 8].
CD38'
,
.
CD38'
.
(
(CD25)
'
'
'
. 2).
(HLA'DR)
.
.
'
.
α
CD25'
2
'
,
'
'
'
'
'
'
[11].
,
[12, 13,
'
'
.
14].
,
D25'
:
2,5
'
,
.
3'
100%
.
1
'
'
,
.
,
1'
'
'
CD3
%
. 1).
CD4
%
'
8
'
CD8
'
,
(
CD4/CD8
,
1'
,
2'
.
4/
52,15±1,49* 39,31±2,71* 44,46±2,14*
1,50±0,15
1,42±0,21
0,80±0,02*
36,46±3,21 33,08±1,53* 26,38±2,57*
%
0,85±0,09
30,20±0,60
0,65±0,08
1,02±0,06
1,03±0,11
23,62±1,46* 27,84±2,35
0,96±0,09* 0,66±0,04
CD4/CD8
1,50±0,05
CD22
%
13,40±0,50
0,28±0,05
21,07±1,71* 21,69±1,12* 22,07±0,90*
0,72±0,08* 0,61±0,04*
0,37±0,02
CD16
%
CD56
%
14,00±0,40
0,30±0,03
12,00±0,20
0,45±0,01
21,92±0,97* 28,85±1,82* 14,53±0,85
0,61±0,09* 0,81±0,07*
0,19±0,02*
21,92±1,26* 18,00±1,30* 17,84±1,62*
0,66±0,08* 0,50±0,03
0,26±0,01*
'
(CD22),
(CD56)
K'
,
,
,
'
(CD16),
'
'
*
3'
64,20±0,70
1,37±0,16
38,50±0,90
,
.
2'
±m
:
1,41±0,05
1,46±0,10
0,37±0,03*
23,38±1,05*
0,41±0,02*
1,12±0,14
.
59
,
CD25'
'
.
,
,
,
Fas'
'
'
'
'
'
.
[11, 12].
'
'
'
'
'
,
,
2
,
Fas'
,
.
.
C. albicans
U. urealyticum.
,
2,
,
'
α
. 2).
(
'
(
'
II
(HLA'DR),
'
,
(
,
'
'
).
,
.
'
HLA'DR/CD95,
D25/CD95
'
'
Fas'
.
HLA'DR/CD95
'
'
.
,
,
.
'
95
'
,
'
.
25/ 95
'
'
'
(
.3).
CD25/CD95
CD38/CD95.
'
HLA'DR,
HLA'DR–
.
,
'
HLA'DR
HLA'DR
.
,
'
[8].
,
,
,
'
'
,
1,5'2'
HLA'DR'
(
38/
,
. 2).
'
,
HLA'DR'
Fas'
.
'
'
'
'
:
C. albicans
. 2).
25/
95
.
'
,
.
U. urealyticum
'
.
CD95'
Fas'
[6].
'
'
'
'
95
,
)
,
U. urealyticum
25/
95
( 2'2,5
'
.
'
C. albicans
,
'
.
2
,
HLA/
,
1'
2'
%
9,00±0,20
0,15±0,09
23,23±2,28* 28,47±1,49* 12,00±1,49*
0,59±0,06* 0,80±0,07* 0,24±0,01
CD38
%
HLA
%
CD95
%
24,10±0,80
0,86±0,10
14,00±0,50
0,34±0,01
12,50±1,00
27,69±0,91* 26,00±1,55 26,69±0,82
0,80±0,08
0,78±0,10
0,51±0,05*
25,69±1,58* 26,84±2,45* 24,46±0,64*
0,53±0,06*
0,86±0,06* 0,44±0,02*
24,15±2,28* 24,92±2,22* 19,70±1,62*
0,64±0,04*
0,62±0,10*
'
.
3'
CD25
0,30±0,02
95
±m
0,43±0,09*
cum
'
U. urealytiq
'
Ch. trachomatis.
,
Fas'
.
U. urealyticum
cans,
C. albiq
,
HLA/
95,
60
3
,
1'
CD38/CD95
CD25/CD95
HLA/CD95
2'
.
.
.
1,92±0,07
2,06±0,05
0,72±0,08
1,24±0,07*
1,25±0,01*
0,90±0,08*
1,25±0,02*
1,09±0,02*
0,95±0,01*
1,29±0,07*
1,32±0,01*
1,01±0,07*
1,14±0,30*
1,24±0,20*
0,96±0,01
1,04±0,13*
1,26±0,01*
1,14±0,17*
1,35±0,15*
1,18±0,25*
0,60±0,12
./
./
./
.
.
.
0,60±0,05
1,12±0,05
1,13±0,01
0,96±0,04
1,02±0,07
1,06±0,03
0,95±0,01*
0,99±0,10
1,00±0,07
1,01±0,04*
1,05±0,05
1,12±1,10
0,91±0,05*
1,06±0,09
0,82±0,08*
1,29±0,07*
1,07±0,01
1,38±0,30
0,55±0,01*
1,24±0,09
0,92±0,02*
4.
'
38/
95.
.,
.,
. – 1992. –
.//
. 14q19.
. 3).
'
5.
.,
(
.3).
,
'
'
,
,
'
.
,
'
2
2'2,5
HLA'DR
1,5'2
.
, 1995.
q
,
Fas'
.
,
CD95'
2
25/
95:
.//
. – 1998. –
,
q
1. – . 10q13.
. – .,
,
.
,
'
,
'
'
'
'
.
1.
2.
3.
.,
.// Int. J. on
6. – C. 132q134.
.,
.//
. – 1999. –
3. – C. 56q59.
.
:
. – .:
, 1999.
12.
.//
.
. – 1999. – . 1,
31q2. – .37q46.
13. Cohen J.J.// Adv. Immunol. – 1991. – Vol. 50. – P. 55q85.
14. Romagnani S.// Immunol. Today. – 1997. – Vol. 18,
suppl. 6. – P. 263q266.
15. TaylorqRobinson D.// Int. J. STD AIDS. – 1998. –
Vol. 9, No. 2. – P. 123q124.
PATIENTS SUFFERING FROM UROGENITAL
»,
CD95'
,
.,
' UREAPLASMIC INFECTION
' Ya.A. Yutskovskaya, E.V. Markelova, A.D. Yutskovsky
.
«
,
.
, 2000.
95
30.05.03.
,
' INDICES OF CELL'MEDIATED IMMUNITY AT
,
,
'
'
'
'
.
.,
.:
8.
. .
2001.
9.
.,
Immunorehabilitation. – 1997. –
10.
.,
'
'
' 11.
.
,
.
,
.–
7.
,
,
6.
9q10. –
.,
. – .:
,
HLA/
3'
./
./
./
(
(CD25)
±m
.,
.//
,
. – 1999. – 3. – . 28q31.
.,
.,
.//
q
6q
q
.–
, 1989. – . 132q133.
.,
.//
q
. – 1993. – 5. – . 22q28.
Vladivostok State Medical University
Summary – The article describes the features of cellular indices
of immune state under different forms of urogenital ureaplasmic
infection. As to monoureaplasmosis there was a decrease in abun'
dance of CD3'lymphocytes and increase in level of B'lympho'
cytes (CD22). Reduction of index of the ratio HLA'DR/CD95
was the evidence of the apoptosis predominance over the pro'
cesses of cellular proliferation and differentiation. Under mixed
infection by U. urealyticum and Ch. trachomatis there was an
immunodeficiency state of combined type characterized by de'
crease in CD3' and CD4'lymphocytes and CD56'(killer) cells,
as well as by disturbances in the ratio of immunoregulation cells
(CD4/CD8), and enhancement of Fas' mediated apoptosis, that
was the evidence of apparent imbalance of regulatory mecha'
nisms. Predominance of the activation processes with consider'
able increase of B'lymphocytes, as well as markers of early and
late cell activation were registered when U. urealyticum was as'
sociated with C. albicans against the background of decrease in
abundance of CD3' and CD4'lymphocytes.
Pacific Medical Journal, 2003, No. 4, p. 57q60.